Navigation Links
IDEXX Laboratories Announces Entry Into Consent Agreement with FTC Bureau of Competition Staff
Date:12/11/2012

WESTBROOK, Maine, Dec. 11, 2012 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ, IDXX) and the staff of the Bureau of Competition of the U.S. Federal Trade Commission ("FTC") have signed a Consent Agreement to resolve the FTC's investigation into whether the Company engaged in unfair methods of competition.

(Logo:  http://photos.prnewswire.com/prnh/20110602/NE13041LOGO)

Under the Consent Agreement, IDEXX cannot have exclusive distribution agreements with all three of MWI Veterinary Supply, Inc. ("MWI"), Butler Schein Animal Health, and Webster Veterinary. IDEXX may maintain exclusive distribution agreements with two of these three distributors. IDEXX's non-exclusive agreement with MWI, effective January 1, 2013, brings the Company into compliance with the terms of the Consent Agreement. 

The Consent Agreement expressly states that the Company admits no wrongdoing.

"Entering into the Consent Agreement with the FTC staff is a milestone in our effort to resolve the multi-year FTC investigation," said Jonathan Ayers, Chairman and Chief Executive Officer. "The terms of the Consent Agreement are consistent with the proposed resolution we described beginning in April of this year."

"We continue to believe that our distribution practices do not violate the antitrust laws, as these same practices have been upheld by two federal courts of appeal. However, the Consent Agreement provides a framework that allows us to put an end to the expense and distraction of the FTC investigation and to avoid long and costly litigation with the FTC, while preserving and even strengthening the longstanding relationships we have with our distribution partners."

As is the ordinary process, the Consent Agreement remains subject to approval by the FTC Commissioners, who will review the Agreement and a draft complaint. If they approve the proposed draft complaint and proposed Consent Agreement, there will be a 30-day public comment period after which the Commissioners can issue their final approval.

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,000 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements

This press release contains statements about the Consent Agreement the Company has entered into with the FTC staff, the impact of the Consent Agreement on the FTC's investigation of the Company's distribution arrangements, and the impact the Consent Agreement may have on the Company's distribution arrangements that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," and similar words and expressions. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the results of the process for approval of the Consent Agreement by the FTC Commissioners; the  impact of one of the Company's distributors becoming non-exclusive on the Company's results of operations; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; and the other factors relating to our business and prospects that are discussed in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, in the section captioned "Risk Factors."

Contact: Merilee Raines, Chief Financial Officer, 1-207-556-8155


'/>"/>
SOURCE IDEXX Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IDEXX Laboratories to Present at Piper Jaffray 24th Annual Healthcare Conference
2. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
3. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
4. Nelson Laboratories to Present Cleaning Validation Guidelines at BIOMEDevice San Jose
5. Vr Laboratories Selects Hsg2001 As Lead Development Candidate For Candida Albicans Program
6. Nelson Laboratories Compliant With New FDA Medical Device Registration Requirement
7. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
8. Ampersand Acquires Willow Laboratories
9. Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
10. Key Considerations for Selecting and Implementing a CAD/CAM System for Dental Laboratories Outlined in Free Article Download from Jensen Dental
11. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... 10, 2017 Radiology has become the number ... have also spiraled to the number one ranking as ... than ever before as the most complete and reliable ... with lower back pain an MRI may confirm a ... pain, resulting in entirely different treatment protocols.  In these ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/6/2017)... 2017   Provista , a proven leader in the ... today announced Jim Cunniff as the company,s new ... business experience to Provista, including most recently serving as the ... California . He assumed his new role with Provista ... fit for Provista," says Jody Hatcher , president, Sourcing ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs included on ... health systems in the nation and help their organizations navigate the challenges in ... been instrumental in developing successful hospital and health system strategy. , Becker's Hospital ...
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a ... CIO Applications magazine has named the company a “Top 25 Cybersecurity Companies 2017.” ... Cloud to help organizations simply and proactively address potential cybersecurity threats before they happen. ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... technology and a 2017 Best in KLAS category winner, has named Daniel P. ... to extend and enhance its technology platform and product offerings,” says Justin Neece, ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... patients on peri-implantitis in Las Vegas, NV, and the importance of ... gum disease consultation and leading care for peri-implantitis, with or without a referral. ...
(Date:5/23/2017)... ... ... New patients with symptoms of gum disease in San Diego, ... treatments from the doctors at Art of Dentistry, without first receiving a referral. Drs. ... of receiving qualified treatment in order to avoid systemic health effects associated with untreated ...
Breaking Medicine News(10 mins):